[Relationship of GSTP1 and XRCC1 gene polymorphisms with chemotherapy sensitivity and prognosis of prostate cancer].

OBJECTIVE

To explore the relationship of glutathione S-transferase P1 (GSTP1) and X-ray repair cross-complementation group 1 (XRCC1) gene polymorphisms with chemotherapy sensitivity and prognosis in patients with prostate cancer (PCa).

METHODS

A total of 103 PCa patients underwent androgen-deprivation therapy + double-agent chemotherapy from May 2018 to May 2021. We collected the clinical data from the patients, determined their genotypes using the PCR-PFLP method, analyzed the association of the locus polymorphisms of GSTP1-rs1695 and XRCC1-rs25487 with chemotherapy sensitivity, and investigated the correlation of GSTP1 and XRCC1 gene polymorphisms with the 3-year survival rate of the patients.

RESULTS

The distribution of GSTP1-rs1695 and XRCC1-rs25487 loci in the 103 PCa patients receiving chemotherapy was consistent with the Hardy-Weinberg equilibrium (χ2 = 9.794, P > 0.05). At the GSTP1-rs1695 locus, the AA genotype accounted for 65.05% (67/103), the AG genotype 23.30% (24/103) and the GG genotype 11.65% (12/103); at the XRCC1-rs25487 locus, the AA genotype accounted for 29.13% (30/103), the AG genotype 50.49% (52/103) and the GG genotype 20.39% (21/103). Chemotherapy sensitivity was significantly lower in the patients with the GSTP1-rs1695 AA type than in those with the AG/GG types (35.82% vs 58.33%, P <0.05), but showed no statistically significant difference between the XRCC1-rs25487 AA and AG/GG types (40.00% vs 45.21%, P > 0.05). There was no statistically significant difference in the 3-year progression-free survival rate between the patients with different GSTP1-rs1695 and XRCC1-rs25487 phenotypes (P > 0.05). The 3-year overall survival rate was lower in the patients with the GSTP1-rs1695 AA type than in those with the AG/GG types, and so was it in those with the XRCC1-rs25487 AA type than in those with the AG/GG types (P < 0.05). Multivariate COX regression analysis showed that the GSTP1-rs1695 AA and XRCC1-rs25487 AA types were independent factors affecting the 3-year overall survival of the patients after chemotherapy.

CONCLUSION

Both GSTP1-rs1695 and XRCC1-rs25487 gene polymorphisms have some influence on chemotherapy sensitivity and prognosis in PCa patients. The A allele mutations of GSTP1-rs1695 and XRCC1-rs25487 can decrease the 3-year survival rate, while their G allele mutations may help improve chemotherapy sensitivity and survival.